Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Vertex Says Hepatitis Study Positive

January 10, 2006

On Monday, biotech firm Vertex Pharmaceuticals Inc. said an early study of its experimental hepatitis C drug VX-950 and pegylated interferon found the combination therapy was more effective at reducing blood levels of the virus than either treatment alone. In the 14-day trial of eight patients, the combination treatment was also well-tolerated. In the next few months, Vertex plans to start a mid-stage study involving more than 200 patients. Depending on results from that study, a Phase III trial could get underway in 2007, the company said.

Back to other news for January 10, 2006

Adapted from:
Associated Press
01.09.06


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement